Remaking the Trial Medication Adherence Space


Sponsored Podcast

IQVIA informs us, new prescriptions for chronic therapies were 20% below what they were before 2020 and telemedicine patient encounters have settled at 10%. Accenture informs us, the low point of in-person pharma rep sales calls over the last year was 35%. These three facts point to lower access to trial medication and give strong impetus for remaking the trial medication adherence space. The CDC informs us that medication non-adherence causes up to 125,000 preventable deaths and $100 billion to 300 billion in preventable medical costs each year. Trial medication is a key solution to medication adherence. Pharmaceutical Commerce asked Hal Walsh, CEO of SymmetryRx, to tell us about the latest digital solutions that truly streamline the route from the manufacturer to the hands of patients in today’s high-tech, low-touch world.

Related Content
© 2024 MJH Life Sciences

All rights reserved.